%0 Journal Article
%T Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
%A Christian Vestergaard
%A Eva Spaun
%A Jon Diernaes
%A Kenneth Thomsen
%A Trine Heide £żllegaard
%J Archive of "Case Reports in Dermatology".
%D 2018
%R 10.1159/000489661
%X Checkpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates of disseminated malignant melanoma (MM). Autoimmune adverse reactions are very common in checkpoint inhibitors. We present 2 cases of bullous pemphigoid, as adverse reactions to pembrolizumab-treated MM
%K Adverse drug reaction
%K Autoimmune bullous diseases
%K Autoimmune diseases
%K Bullous pemphigoid
%K Bullous skin disease
%K Malignant melanoma
%K Pembrolizumab
%K Programmed cell death 1
%K Checkpoint inhibitors
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047493/